Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dYeyCduTtWCeAyiwCidmzaCicNEDcD
| Today's Top Story |  |  | | - Oxford, Menarini join forces to develop antibody-based cancer drugs
Oxford BioTherapeutics and Menarini agreed to jointly develop antibody-based oncology drugs, and the deal will cover five of OBT's antibody and antibody-drug conjugate programs. Menarini will be in charge of early clinical development and manufacturing. Once the drugs pass proof-of-concept tests, OBT will take over clinical development and marketing of the drugs in North America and Japan, while Menarini will get the rights to develop and sell the drugs in Europe, Asia, the Commonwealth of Independent States and Latin America. The partnership's investment could surpass $1 billion, Menarini said. Genetic Engineering & Biotechnology News (10/29)       | - FDA expedites review of Bayer's regorafenib
Bayer obtained priority-review status from the FDA for regorafenib as a treatment for gastrointestinal stromal tumors. The drug would be sold as Stivarga and marketed jointly in the U.S. with Onyx Pharmaceuticals. Reuters (10/29) - Coalition aims to standardize clinical trial data reporting
The FDA joined the Clinical Data Interchange Standards Consortium and the Critical Path Institute to form the Coalition For Accelerating Standards and Therapies to develop and maintain data standards regarding individual diseases and therapeutic areas. CFAST will bring together experts in health care technology, government and the drug industry to develop standards so that data from multiple trials regarding the same therapeutic area or disease can be more easily grouped for analysis and reporting. Express Pharma (10/25)  | Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenges faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio. | |
| Company & Financial News | | | | | Global Developments | | | | - Consortium launches France's first cell therapy factory
The C4C consortium of government agencies and biotechnology companies has established a cell therapy factory in Les Ulis, France. The facility is designed to become a development and manufacturing hub for cell-based treatments. The project received about $100 million from consortium members and almost $40 million from OSEO, France's state innovation agency. In-PharmaTechnologist.com (10/29) | Food & Agriculture | | | | - Scientists slam recommendation to suspend biotech crop trials in India
Biotechnologists, agricultural scientists and agribiotech industry leaders criticized the recommendation of a court-appointed panel to suspend trials and commercialization of biotech crops in India for 10 years. The ban could hurt Indian farmers the most as they need to boost food production to meet the needs of the growing population, the scientists said. The recommended moratorium and dismissal of safety data are not based on science, said the former director of the Indian Institute of Science. Business Standard (India) (10/29) | Industrial & Environmental | | | | | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | A teacher affects eternity; he can never tell where his influence stops."
--Henry Adams,
American journalist, historian, academic and novelist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, October 29, 2012
- Friday, October 26, 2012
- Thursday, October 25, 2012
- Wednesday, October 24, 2012
- Tuesday, October 23, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment